J. Piotrowski et al., SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO ANTIMICROBIAL AGENTS - EFFECT OF EBROTIDINE AND RANTIDINE, Journal of Physiology and Pharmacology, 46(4), 1995, pp. 463-469
Convincing evidence now exists that infection with H. pylori is a prim
ary factor in the pathogenesis of gastric disease, and new therapy reg
imens include a combination of H-2 blockers with antimicrobial agents.
In this study, was assessed the efect of ebrotidine and ranitidine on
the in vitro anti-H. pylori activity of amoxicillin, erythromycin, te
tracycline, and metronidazole. The assays of the antiulcer drugs alone
gave MIC value of 150 mg/L for ebrotidine and 1600 mg/L for ranitidin
e. Inclusion of ebrotidine in the antimicrobial agent assays evoked at
its optimal concentration of 75 mg/L a 28% enhancement in the MIC of
metronidazole, 2.5-fold enhancement in the MIC of erythromycin, 2-fold
in amoxicillin and 1.7-fold in tetracycline, while ranitidine caused
noticeable changes in the MIC values of the tested antimicrobial agent
s only a the dose of 1600 mg/L. The results demonstrate that ebrotidin
e enhances anti-H. pylori activity of antimicrobial agents at doses we
ll below that of rantidine.